Search | Clinical Trials Finder

Conditions: Acute Decompensated Heart Failure
Interventions: Experimental: Placebo, Experimental: Metolazone; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Crohn's Disease, Complex Perianal Fistula
Interventions: Placebo, Darvadstrocel; Other · Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 22
States / cities: San Francisco, California • West Hollywood, California • New Haven, Connecticut + 17 more

Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions: Micronized progesterone, Spironolactone, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Asthma
Interventions: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoarthritis, Knee
Interventions: PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 25
States / cities: Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more

Conditions: Friedreich's Ataxia
Interventions: VP 20629, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: Healthy
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 55 Years to 83 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT 60 µg, RSV MAT 120 µg, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more

Conditions: End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC); Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy, Alzheimer Disease
Interventions: AL003, Saline Solution; Biological · Other
Lead sponsor: Alector Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Delray Beach, Florida • Lady Lake, Florida • Orlando, Florida + 2 more

Conditions: Asthma, Bronchospasm
Interventions: albuterol inhalation powder, Placebo, albuterol inhalation aerosol; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: San Jose, California • Centennial, Colorado • Denver, Colorado + 1 more

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
Interventions: Indomethacin, Placebo; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 0 Hours to 12 Hours
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Roseville, California • Sacramento, California • Pittsburgh, Pennsylvania + 1 more

Conditions: Healthy Participants
Interventions: BMS-986331, Placebo, Matching BMS-986331; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Anaheim, California • Lenexa, Kansas

Conditions: Anemia, Sickle Cell, Pain
Interventions: Fentanyl Citrate, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Spasticity
Interventions: Corabotase, Placebo, Dysport; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more

Conditions: Healthy
Interventions: Pregabalin, Placebo, Bowel preparation; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: PRO 140; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more

Conditions: Growth Hormone Deficiency
Interventions: ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg; Drug
Lead sponsor: Aileron Therapeutics, Inc.; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

Safety and Efficacy of a Drug Delivery System in Glaucoma

Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia

Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

First in Human Study for Safety and Tolerability of AL003.

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Pregabalin and Colonic Function

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects